TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7853452

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation (VS) strength training for the arms and conventional stretching exercises for the legs
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Conventional exercises for strength of the arms and VS stretching exercises for the legs
Number of subjects: 28

Group type: COMPARATOR
Intervention: Irrelevant training (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation (VS) flexibility training
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Conventional training
Number of subjects: 28
Study: 2685660

Group type: EXPERIMENTAL
Intervention: 300 mg of gangliosides (Cronassial)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 954734

Group type: EXPERIMENTAL
Intervention: Progressive, step increment, discontinuous tests (DCT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Progressive, step increment, continuous test (CT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Constant load tests (CL and CL + 2 1/2%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Discontinuous and continuous progressive tests
Number of subjects: 10
Study: 31526874

Group type: EXPERIMENTAL
Intervention: Phase II trials
Number of subjects: 57

Group type: COMPARATOR
Intervention: Phase III trials
Number of subjects: 57
Study: 28278194

Group type: EXPERIMENTAL
Intervention: Spectral tissue sensing (STS)
Number of subjects: 19
Study: 25337948

Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered cognitive behavior therapy (ICBT) for insomnia
Number of subjects: 43

Group type: COMPARATOR
Intervention: Guided Internet-delivered cognitive behavior therapy (ICBT) for depression
Number of subjects: 43
Study: 23037929

Group type: EXPERIMENTAL
Intervention: Mulligan's technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Passive stretching exercises
Number of subjects: 40
Study: 22133239

Group type: EXPERIMENTAL
Intervention: Supervised muscle strengthening, flexibility, and endurance training (60 minutes, 3 times per week for 2 months)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No direct intervention (Control group)
Number of subjects: 75
Study: 20079223

Group type: EXPERIMENTAL
Intervention: Domestic Orlistat 120 mg 3 times a day with an energy-controlled diet for 24 weeks
Number of subjects: 228

Group type: COMPARATOR
Intervention: Imported Orlistat 120 mg 3 times a day with an energy-controlled diet for 24 weeks
Number of subjects: 228
Study: 16395076

Group type: EXPERIMENTAL
Intervention: Immune enhancing (IE) diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular formula
Number of subjects: 40
Study: 14991119

Group type: EXPERIMENTAL
Intervention: Cystectomy for non-urothelial indications
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cystectomy for transitional cell cancer of the bladder
Number of subjects: 42
Study: 10943576

Group type: EXPERIMENTAL
Intervention: GyneFix IUD
Number of subjects: 313

Group type: COMPARATOR
Intervention: TCu380A IUD
Number of subjects: 313
Study: 8823584

Group type: EXPERIMENTAL
Intervention: 1-quadrant sub-Tenon's anesthesia (1-QST)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 570
Study: 1309865

Group type: EXPERIMENTAL
Intervention: DMSA (1050 mg/m2 per day for 5 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: CaNa2EDTA (1000 mg/m2 per day intravenously)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: DMSA (350 or 700 mg/m2 per day for 14 days on outpatient basis)
Number of subjects: 19
Study: 6331037

Group type: EXPERIMENTAL
Intervention: 10 mg naloxone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.4 mg naloxone
Number of subjects: 8

Group type: COMPARATOR
Intervention: 4.8 mg naloxone
Number of subjects: 8
Study: 30193845

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 60

Group type: COMPARATOR
Intervention: SHAM condition
Number of subjects: 60
Study: 26044855

Group type: EXPERIMENTAL
Intervention: FAHF‐2 (n = 46)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 68
Study: 23991522

Group type: EXPERIMENTAL
Intervention: Feedback and explanation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Feedback
Number of subjects: 33

Group type: COMPARATOR
Intervention: Explanation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Feedback researcher explains
Number of subjects: 33

Group type: COMPARATOR
Intervention: Feedback child explains
Number of subjects: 33
Study: 21421768

Group type: EXPERIMENTAL
Intervention: Breastfeeding confederate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sexualized breast condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 0
Study: 18344081

Group type: EXPERIMENTAL
Intervention: Lornoxicam/morphine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 100
Study: 16369704

Group type: EXPERIMENTAL
Intervention: D3 surgery
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Nodal dissection
Number of subjects: 221
Study: 14555566

Group type: EXPERIMENTAL
Intervention: Specific Expiratory Muscle Training (SEMT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Specific Inspiratory Muscle Training (SIMT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SEMT + SIMT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (very low load training)
Number of subjects: 32
Study: 10700888

Group type: EXPERIMENTAL
Intervention: M-VAC (MTX + VBL + ADM + CDDP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant or adjuvant cisplatin-based regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy with interferon or interleukin-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant interferon-alpha administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-based treatment protocols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with autologous stem-cell support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximal androgen blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen depletion treatment
Number of subjects: 0
Study: 8683544

Group type: EXPERIMENTAL
Intervention: Exercise interventions
Number of subjects: 11
Study: 1890264

Group type: EXPERIMENTAL
Intervention: Food challenges
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo challenges
Number of subjects: 11
Study: 6362585

Group type: EXPERIMENTAL
Intervention: Fibronectin-rich plasma cryoprecipitate (2.139 +/‐ 0.161 mg/ml)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fibronectin-poor cryoprecipitate extracted plasma (placebo, 0.116 +/‐ 0.025 mg/ml)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fibronectin-rich plasma cryoprecipitate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fibronectin-poor cryoprecipitate extracted plasma (placebo)
Number of subjects: 14
Study: 3887350

Group type: EXPERIMENTAL
Intervention: Nd‐YAG laser treatment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 104
Study: 29124407

Group type: EXPERIMENTAL
Intervention: TAPP educational system (intervention group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional training system (control group)
Number of subjects: 18
Study: 27655166

Group type: EXPERIMENTAL
Intervention: Lapatinib-capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 0
Study: 24323565

Group type: EXPERIMENTAL
Intervention: Early-treated Parkinson's disease cohort
Number of subjects: 1737
Study: 23532991

Group type: EXPERIMENTAL
Intervention: Structured weight loss program (dietary modifications, increased physical activity, behavioral changes)
Number of subjects: 332
Study: 19930408

Group type: EXPERIMENTAL
Intervention: Early corticosteroid withdrawal (ECSWD)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Chronic corticosteroid therapy (CCST)
Number of subjects: 151
Study: 18077495

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine capsule
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16368828

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PATS 40 microg for 24 hours
Number of subjects: 484

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PATS
Number of subjects: 484
Study: 12925475

Group type: EXPERIMENTAL
Intervention: Acetaminophen 40 mg/kg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ibuprofen 15 mg/kg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen and ibuprofen
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 10717327

Group type: EXPERIMENTAL
Intervention: gemcitabine/cisplatin (GC)
Number of subjects: 135

Group type: COMPARATOR
Intervention: cisplatin/etoposide (CE)
Number of subjects: 135
Study: 8789772

Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Salbutamol and placebo
Number of subjects: 59

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 59
Study: 1523287

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6823474

Group type: COMPARATOR
Intervention: Supervised laboratory section (Section 1)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Independent laboratory sections (Section 2 and Section 3)
Number of subjects: 57
Study: 30942842

Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention (case management, audit and feedback reports, distribution of educational materials)
Number of subjects: 1619

Group type: COMPARATOR
Intervention: Routine practice (control group)
Number of subjects: 1619

Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention
Number of subjects: 1619
Study: 26969421

Group type: EXPERIMENTAL
Intervention: NACP-containing composite
Number of subjects: 24

Group type: COMPARATOR
Intervention: Transbond XT (control)
Number of subjects: 24
Study: 26316567

Group type: COMPARATOR
Intervention: Solitaire FR
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Merci retriever
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Rescue therapy with intra-arterial rtPA
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Basal ganglionic hemorrhage
Number of subjects: 144
Study: 23543092

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 121

Group type: COMPARATOR
Intervention: Matched control condition
Number of subjects: 121
Study: 21305483

Group type: EXPERIMENTAL
Intervention: Protocol 1 (10 J, 20 J, 50 J, 100 J, 200 J)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Protocol 2 (20 J, 50 J, 100 J, 200 J)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Protocol 1 and Protocol 2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AFl patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Initial energy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 50 J
Number of subjects: 50
Study: 19857068

Group type: EXPERIMENTAL
Intervention: Fenugreek bread (5% fenugreek, 56 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Whole wheat bread (control)
Number of subjects: 8
Study: 16406915

Group type: EXPERIMENTAL
Intervention: Combination therapy with doxazosin and finasteride
Number of subjects: 3047

Group type: COMPARATOR
Intervention: Doxazosin alone
Number of subjects: 3047

Group type: COMPARATOR
Intervention: Finasteride alone
Number of subjects: 3047
Study: 15366728

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication by experienced surgeons
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparoscopic intervention
Number of subjects: 100
Study: 11562727

Group type: EXPERIMENTAL
Intervention: Scheme I: chloroquine phosphate (150 mg) at 25mg/kg/day for three days (10mg/kg on day 1, 7.5mg/kg on days 2 and 3) plus primaquine (15 mg) at 0.25mg/kg/day for fourteen days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Scheme II: chloroquine in a single dose of 10mg/kg plus primaquine at 0.5mg/kg/day for seven days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Scheme III: chloroquine in a single dose of 10mg/kg plus primaquine at 0.5mg/kg/day for five days
Number of subjects: 120
Study: 9535953

Group type: EXPERIMENTAL
Intervention: Catchlike-inducing trains (CITs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Constant-frequency trains (CFTs)
Number of subjects: 12
Study: 8162980

Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 2 l.min‐1 at rest
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Daily activities (as reported in questionnaire)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (prescribed based on blood gas measurements at rest)
Number of subjects: 34
Study: 3202450

Group type: EXPERIMENTAL
Intervention: Inhaled histamine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 6
Study: 4939600

Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg four times daily for four weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Salbutamol 2 mg four times daily for four weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31219755

Group type: EXPERIMENTAL
Intervention: Superior hypogastric nerve block (SHNB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 0
Study: 27317878

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of tenofovir disoproxil fumarate/lamivudine/efavirenz 300/300/600 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Individual innovator products
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 48
Study: 25381449

Group type: EXPERIMENTAL
Intervention: OPUS treatment
Number of subjects: 547

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 547
Study: 23783829

Group type: COMPARATOR
Intervention: Standard physical activity recommendation
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Self‐administered implementation intention
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Telephone‐assisted implementation intention
Number of subjects: 423
Study: 21696265

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo (Pbo)
Number of subjects: 313
Study: 20209978

Group type: EXPERIMENTAL
Intervention: Acupuncture + Rehabilitation (Acup + Rehab)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rehabilitation (Rehab)
Number of subjects: 50
Study: 16825290

Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of VEGF‐A(165) plasmid followed by G‐CSF (10 microg/kg/day for 6 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intramyocardial injections of VEGF‐A(165) plasmid
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intramyocardial injections of placebo
Number of subjects: 16
Study: 15210258

Group type: EXPERIMENTAL
Intervention: IMCI training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IMCI training in bilingual consultations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IMCI training in monolingual (Bambara) consultations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug consultations in French and Bambara
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IMCI training overall
Number of subjects: 0
Study: 11058663

Group type: EXPERIMENTAL
Intervention: Breast biphasic compression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard monophasic compression
Number of subjects: 0
Study: 9286849

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1116
Study: 8269656

Group type: EXPERIMENTAL
Intervention: Blood flow rate of 250 cc/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Blood flow rate of 350 cc/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Blood flow rate of 450 cc/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison between the three different blood flow rates (250, 350, 450 cc/min)
Number of subjects: 10
Study: 3318438

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30445682

Group type: EXPERIMENTAL
Intervention: Synergy 1 (10 g)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 34
Study: 27676142

Group type: EXPERIMENTAL
Intervention: Moderate continuous exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High‐intensity interval exercise
Number of subjects: 10
Study: 25306258

Group type: EXPERIMENTAL
Intervention: MuGard
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline-bicarbonate control
Number of subjects: 20
Study: 22677192

Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study: 20971245

Group type: EXPERIMENTAL
Intervention: LOW group (target INR range of 1.8 to 2.8 for aortic valve replacement and 2.5 to 3.5 for mitral or double valve replacement)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: VL1 group (target INR set at 2.0, range 1.6 to 2.1 for aortic valve replacement)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: VL2 group (target INR set at 2.3, range 2.0 to 2.5 for mitral or double valve replacement)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: LOW group
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: VL1 group
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: VL2 group
Number of subjects: 1137

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 1137
Study: 19019658

Group type: EXPERIMENTAL
Intervention: Desflurane F(D) of 6.5% for 15 minutes followed by 5.5% thereafter
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: O(2)/N(2)O FGF setting change from 6 to 0.7 L per minute after three minutes
Number of subjects: 42
Study: 16898280

Group type: EXPERIMENTAL
Intervention: Self-regulation training (two-phase)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-regulation training (three-phase)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 12805060

Group type: EXPERIMENTAL
Intervention: AML with 11q23/MLL rearrangement
Number of subjects: 54

Group type: COMPARATOR
Intervention: De novo AML with MLL rearrangement
Number of subjects: 54

Group type: COMPARATOR
Intervention: therapy‐related AML (t‐AML)
Number of subjects: 54

Group type: COMPARATOR
Intervention: t(9;11) MLL rearrangements
Number of subjects: 54

Group type: COMPARATOR
Intervention: Other MLL rearrangements
Number of subjects: 54

Group type: COMPARATOR
Intervention: AML M4, M5a, and M5b subtypes
Number of subjects: 54

Group type: COMPARATOR
Intervention: All other FAB subtypes
Number of subjects: 54
Study: 10739409

Group type: EXPERIMENTAL
Intervention: 1.0 mg/day of haloperidol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 2.5 mg/day of haloperidol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5.0 mg/day of haloperidol (for non-responders)
Number of subjects: 22
Study: 8796820

Group type: EXPERIMENTAL
Intervention: Intravenous fluid bolus with 1 L of normal saline administered over 30 minutes
Number of subjects: 13

Group type: COMPARATOR
Intervention: No hydration (control group)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Comparison of hydration vs no hydration
Number of subjects: 13
Study: 8198236

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3127916

Group type: EXPERIMENTAL
Intervention: Intravenous DDAVP (0.3 micrograms/Kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Subcutaneous DDAVP (0.3 micrograms/Kg)
Number of subjects: 14
Study: 29764629

Group type: EXPERIMENTAL
Intervention: Serious Game (SG)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Text-Based Scenario (TBS)
Number of subjects: 117
Study: 26739272

Group type: EXPERIMENTAL
Intervention: Participatory women's group intervention
Number of subjects: 5355

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5355
Study: 25763525

Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 76
Study: 24506387

Group type: EXPERIMENTAL
Intervention: 3g of a 1:1 mix of c9‐t11 and t10‐c12 in skimmed milk
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3g olive oil (placebo)
Number of subjects: 38
Study: 21177801

Group type: COMPARATOR
Intervention: Dietary intervention with a focus on habitual dietary patterns
Number of subjects: 160
Study: 18509204

Group type: EXPERIMENTAL
Intervention: HRQoL intervention group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 16547088

Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg ml(-1) (0.2%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prilocaine 5 mg ml(-1) (0.5%)
Number of subjects: 60
Study: 14585084

Group type: EXPERIMENTAL
Intervention: Human GH 0.1 IU/kg per day for 4 days
Number of subjects: 23
Study: 10924807

Group type: EXPERIMENTAL
Intervention: High dose fentanyl (112 microg bolus followed by 0.04 microg/kg per min infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low dose fentanyl (56 microg bolus followed by 0.02 microg/kg per min infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (50 cc bolus followed by 45 cc/h infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fentanyl (both doses)
Number of subjects: 20
Study: 7796344

Group type: EXPERIMENTAL
Intervention: 100 IU of salmon calcitonin intranasally daily for 1 year
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo intranasal spray daily for 1 year
Number of subjects: 150
Study: 2121325

Group type: COMPARATOR
Intervention: Nitroglycerin (1.5 micrograms/kg/min) alone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (1.5 micrograms/kg/min) with oral captopril (63 +/- 8 mg/day)
Number of subjects: 19
Study: 619947

Group type: EXPERIMENTAL
Intervention: Clonidine (300 μg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: UK-14,304 (750 μg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5